Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Pomegranate extract a biopesticide for speck

A study funded by the Italian Ministry of Agriculture, Food and Forestry has shown that pomegranate peel extracts can offer efficient control of tomato bacterial speck ( Pseudomonas syringae pv tomato). Ethanol extracts of pomegranate fruit peels inhibited infection by a highly virulent strain of the pathogen for at least 15 days, and could offer a realistic alternative to copper-based sprays commonly used to control the disease. The researchers identified the active components in the extracts as ellagic and gallic acids. Further investigations are being carried out to understand more thoroughly their role in pomegranate peel extract and antibacterial efficacy against different bacterial plant pathogens, as well as their large-scale use in disease management. The activity of this plant extract might provide new opportunities to improve control of different bacterial tomato diseases, including bacterial speck, spot, canker and pith necrosis, the researchers note. Details of the study have been published in the journal, Crop Protection.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts